Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments
CONCLUSIONS: Individuals with Medicaid and commercial insurance received high-priced treatments in similar proportion, after accounting for differences in case mix. However, modification by provider characteristics suggests that insurance type may influence treatment selection for some patient groups. Further work is needed to determine the relationship between insurance status and newer, high-price drugs such as immune-oncology agents.PMID:38484395 | DOI:10.1093/oncolo/oyae035 (Source: The Oncologist)
Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Aaron P Mitchell Alan C Kinlaw Sharon Peacock-Hinton Stacie B Dusetzina Aaron N Winn Hanna K Sanoff Jennifer L Lund Source Type: research
Statewide Cancer Drug Repository Reducing Waste in the Setting of Shortage Crisis
This article introduces pilot outcomes for a solution to improve access to medications while also decreasing medication waste. Cancer drug repositories are an innovative patient-centered model where donations of unused cancer medications from patients are repurposed and provided to patients who are most vulnerable and disproportionately harmed by financial toxicity. This model demonstrates efficiency and sustainability that complements integrated care and provides an approach to increase medication access and decrease medication waste.PMID:38484400 | DOI:10.1093/oncolo/oyae040 (Source: The Oncologist)
Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Emily R Mackler Siobhan Norman Farah Jalloul Source Type: research
Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments
CONCLUSIONS: Individuals with Medicaid and commercial insurance received high-priced treatments in similar proportion, after accounting for differences in case mix. However, modification by provider characteristics suggests that insurance type may influence treatment selection for some patient groups. Further work is needed to determine the relationship between insurance status and newer, high-price drugs such as immune-oncology agents.PMID:38484395 | DOI:10.1093/oncolo/oyae035 (Source: The Oncologist)
Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Aaron P Mitchell Alan C Kinlaw Sharon Peacock-Hinton Stacie B Dusetzina Aaron N Winn Hanna K Sanoff Jennifer L Lund Source Type: research
Statewide Cancer Drug Repository Reducing Waste in the Setting of Shortage Crisis
This article introduces pilot outcomes for a solution to improve access to medications while also decreasing medication waste. Cancer drug repositories are an innovative patient-centered model where donations of unused cancer medications from patients are repurposed and provided to patients who are most vulnerable and disproportionately harmed by financial toxicity. This model demonstrates efficiency and sustainability that complements integrated care and provides an approach to increase medication access and decrease medication waste.PMID:38484400 | DOI:10.1093/oncolo/oyae040 (Source: The Oncologist)
Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Emily R Mackler Siobhan Norman Farah Jalloul Source Type: research
Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma
We present a 54-year-old White male with a diagnosis of stage IV pancreatic neuroendocrine carcinoma. Next-generation sequencing of the tumor/blood identified a complex tumor genome, which included a rearranged during transfection (RET) gene fusion. The patient initially received cytotoxic chemotherapy with a significant radiographic response. After 4 cycles of chemotherapy, the patient was transitioned to a clinical trial using selpercatinib, a RET inhibitor, as maintenance therapy. Unfortunately, our patient developed progression of disease at the first treatment monitoring scan. Our patient suffered primary resistance t...
Source: The Oncologist - March 13, 2024 Category: Cancer & Oncology Authors: Blake J McKinley Tucker W Coston Jason S Starr Source Type: research
Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody
CONCLUSIONS: For patients with initially unresectable HCC and PVTT who were successfully converted by the triple combination therapy, salvage liver resection may not be necessary, especially for the patients with CR or types III-IV PVTT.PMID:38478404 | DOI:10.1093/oncolo/oyae032 (Source: The Oncologist)
Source: The Oncologist - March 13, 2024 Category: Cancer & Oncology Authors: Lei Wang Jin-Kai Feng Chong-De Lu Jia-Yi Wu Bin Zhou Kang Wang Xu-Biao Wei Chao Liang Hong-Kun Zhou Jie Shi Wei-Xing Guo Wan Yee Lau Mao-Lin Yan Shu-Qun Cheng Source Type: research
Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma
CONCLUSIONS: In this cohort of heavily pretreated patients with advanced ccRCC, tivozanib yielded a modest clinical benefit in a minority of patients who received prior ICT, cabozantinib, and lenvatinib ± everolimus. TRAEs were consistent with previously published reports.PMID:38478923 | DOI:10.1093/oncolo/oyae037 (Source: The Oncologist)
Source: The Oncologist - March 13, 2024 Category: Cancer & Oncology Authors: Andrew C Johns Matthew T Campbell Mamie Gao Andrew W Hahn Zita Lim Emily Wang Jianjun Gao Amishi Y Shah Pavlos Msaouel Nizar M Tannir Source Type: research
Primary Resistance to RET Inhibition in a RET Fusion-Positive Pancreatic Neuroendocrine Carcinoma
We present a 54-year-old White male with a diagnosis of stage IV pancreatic neuroendocrine carcinoma. Next-generation sequencing of the tumor/blood identified a complex tumor genome, which included a rearranged during transfection (RET) gene fusion. The patient initially received cytotoxic chemotherapy with a significant radiographic response. After 4 cycles of chemotherapy, the patient was transitioned to a clinical trial using selpercatinib, a RET inhibitor, as maintenance therapy. Unfortunately, our patient developed progression of disease at the first treatment monitoring scan. Our patient suffered primary resistance t...
Source: The Oncologist - March 13, 2024 Category: Cancer & Oncology Authors: Blake J McKinley Tucker W Coston Jason S Starr Source Type: research
Salvage Surgery for Initially Unresectable HCC With PVTT Converted by Locoregional Treatment Plus Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody
CONCLUSIONS: For patients with initially unresectable HCC and PVTT who were successfully converted by the triple combination therapy, salvage liver resection may not be necessary, especially for the patients with CR or types III-IV PVTT.PMID:38478404 | DOI:10.1093/oncolo/oyae032 (Source: The Oncologist)
Source: The Oncologist - March 13, 2024 Category: Cancer & Oncology Authors: Lei Wang Jin-Kai Feng Chong-De Lu Jia-Yi Wu Bin Zhou Kang Wang Xu-Biao Wei Chao Liang Hong-Kun Zhou Jie Shi Wei-Xing Guo Wan Yee Lau Mao-Lin Yan Shu-Qun Cheng Source Type: research
Efficacy, Safety, and Tolerability of Tivozanib in Heavily Pretreated Patients With Advanced Clear Cell Renal Cell Carcinoma
CONCLUSIONS: In this cohort of heavily pretreated patients with advanced ccRCC, tivozanib yielded a modest clinical benefit in a minority of patients who received prior ICT, cabozantinib, and lenvatinib ± everolimus. TRAEs were consistent with previously published reports.PMID:38478923 | DOI:10.1093/oncolo/oyae037 (Source: The Oncologist)
Source: The Oncologist - March 13, 2024 Category: Cancer & Oncology Authors: Andrew C Johns Matthew T Campbell Mamie Gao Andrew W Hahn Zita Lim Emily Wang Jianjun Gao Amishi Y Shah Pavlos Msaouel Nizar M Tannir Source Type: research
Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma
CONCLUSIONS: Our study highlights the value of NGS in detecting BRAF, NRAS mutations and RAF fusions, expanding possibilities for targeted therapies in malignant melanoma. Belvarafenib showed clinical benefit in patients harboring these alterations. Ongoing trials will provide further insights into the safety and efficacy of belvarafenib.PMID:38470950 | DOI:10.1093/oncolo/oyae018 (Source: The Oncologist)
Source: The Oncologist - March 12, 2024 Category: Cancer & Oncology Authors: Kyoo Hyun Kim Sungmin Cho Yeyeong Jeong Eun Sil Baek Chung Lee Hyang-Joo Ryu Young Su Noh Yoon-Hee Hong Kee Yang Chung Mi Ryung Roh Byung Ho Oh Chang Gon Kim Minkyu Jung Sang Joon Shin Source Type: research
Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma
CONCLUSIONS: Our study highlights the value of NGS in detecting BRAF, NRAS mutations and RAF fusions, expanding possibilities for targeted therapies in malignant melanoma. Belvarafenib showed clinical benefit in patients harboring these alterations. Ongoing trials will provide further insights into the safety and efficacy of belvarafenib.PMID:38470950 | DOI:10.1093/oncolo/oyae018 (Source: The Oncologist)
Source: The Oncologist - March 12, 2024 Category: Cancer & Oncology Authors: Kyoo Hyun Kim Sungmin Cho Yeyeong Jeong Eun Sil Baek Chung Lee Hyang-Joo Ryu Young Su Noh Yoon-Hee Hong Kee Yang Chung Mi Ryung Roh Byung Ho Oh Chang Gon Kim Minkyu Jung Sang Joon Shin Source Type: research
Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
CONCLUSIONS: Despite the rate of PEPI score 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, HER2-negative breast cancer. To clarify the safety and efficacy of this strategy, further investigation is warranted.CLINICAL TRIAL REGISTRATION: ChiCTR2100046678.PMID:38459836 | DOI:10.1093/oncolo/oyae033 (Source: The Oncologist)
Source: The Oncologist - March 9, 2024 Category: Cancer & Oncology Authors: Hongmeng Zhao Dan Li Qian Li Bin Zhang Chunhua Xiao Ying Zhao Jie Ge Yue Yu Yumian Jia Xiaojing Guo Xuchen Cao Xin Wang Source Type: research
Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
CONCLUSIONS: Despite the rate of PEPI score 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, HER2-negative breast cancer. To clarify the safety and efficacy of this strategy, further investigation is warranted.CLINICAL TRIAL REGISTRATION: ChiCTR2100046678.PMID:38459836 | DOI:10.1093/oncolo/oyae033 (Source: The Oncologist)
Source: The Oncologist - March 9, 2024 Category: Cancer & Oncology Authors: Hongmeng Zhao Dan Li Qian Li Bin Zhang Chunhua Xiao Ying Zhao Jie Ge Yue Yu Yumian Jia Xiaojing Guo Xuchen Cao Xin Wang Source Type: research
Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
CONCLUSIONS: Despite the rate of PEPI score 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, HER2-negative breast cancer. To clarify the safety and efficacy of this strategy, further investigation is warranted.CLINICAL TRIAL REGISTRATION: ChiCTR2100046678.PMID:38459836 | DOI:10.1093/oncolo/oyae033 (Source: The Oncologist)
Source: The Oncologist - March 9, 2024 Category: Cancer & Oncology Authors: Hongmeng Zhao Dan Li Qian Li Bin Zhang Chunhua Xiao Ying Zhao Jie Ge Yue Yu Yumian Jia Xiaojing Guo Xuchen Cao Xin Wang Source Type: research